Silo Pharma Stock Performance
| SILO Stock | USD 1.38 0.01 0.72% |
Silo Pharma holds a performance score of 9 on a scale of zero to a hundred. The entity has a beta of 0.51, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Silo Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Silo Pharma is expected to be smaller as well. Use Silo Pharma rate of daily change, period momentum indicator, as well as the relationship between the expected short fall and maximum drawdown , to analyze future returns on Silo Pharma.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Silo Pharma are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very abnormal essential indicators, Silo Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 11.4 M |
Silo |
Silo Pharma Relative Risk vs. Return Landscape
If you would invest 88.00 in Silo Pharma on December 20, 2024 and sell it today you would earn a total of 50.00 from holding Silo Pharma or generate 56.82% return on investment over 90 days. Silo Pharma is currently generating 1.0801% in daily expected returns and assumes 8.8587% risk (volatility on return distribution) over the 90 days horizon. In different words, 79% of otc stocks are less volatile than Silo, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Silo Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silo Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Silo Pharma, and traders can use it to determine the average amount a Silo Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1219
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SILO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.86 actual daily | 79 79% of assets are less volatile |
Expected Return
| 1.08 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Silo Pharma is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Silo Pharma by adding it to a well-diversified portfolio.
Silo Pharma Fundamentals Growth
Silo OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Silo Pharma, and Silo Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silo OTC Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (53.47) % | ||||
| Current Valuation | (2.06 M) | ||||
| Shares Outstanding | 2.84 M | ||||
| Price To Earning | 118.39 X | ||||
| Price To Book | 0.93 X | ||||
| Price To Sales | 77.69 X | ||||
| Revenue | 72.1 K | ||||
| EBITDA | (3.86 M) | ||||
| Cash And Equivalents | 8.85 M | ||||
| Cash Per Share | 4.45 X | ||||
| Book Value Per Share | 2.12 X | ||||
| Cash Flow From Operations | (3.22 M) | ||||
| Earnings Per Share | (1.18) X | ||||
| Total Asset | 7.75 M | ||||
| Retained Earnings | (10.87 M) | ||||
About Silo Pharma Performance
By examining Silo Pharma's fundamental ratios, stakeholders can obtain critical insights into Silo Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Silo Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.Things to note about Silo Pharma performance evaluation
Checking the ongoing alerts about Silo Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Silo Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Silo Pharma is way too risky over 90 days horizon | |
| Silo Pharma may become a speculative penny stock | |
| Silo Pharma appears to be risky and price may revert if volatility continues | |
| Silo Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 72.1 K. Net Loss for the year was (3.63 M) with profit before overhead, payroll, taxes, and interest of 66.26 K. | |
| Silo Pharma currently holds about 8.85 M in cash with (3.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Silo Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silo Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Silo Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Silo Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silo Pharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Silo Pharma's otc stock. These opinions can provide insight into Silo Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.